Amarantus to Present at ICV Sonoma Event
SAN FRANCISCO, January 15, 2016 /PRNewswire/ --
Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapies in Regenerative Medicine and Orphan disease, today announced the Company will be presenting at the ICV Sonoma event. The conference is being held January 14-16, 2016 at Sonoma Golf Club in Sonoma, California. Gerald E. Commissiong, President and CEO of Amarantus, will present on Friday, January 15th, 2016 2:30pm Pacific Time.
Mr. Commissiong will discuss details regarding a pending Amarantus Diagnostics, Inc. spin-out transaction into a publicly-traded, immuno-oncology-focused diagnostics company.
Further information about ICV Sonoma can be found at: http://www.icvevents.com/event/icv-sonoma/
About Amarantus Diagnostics
Amarantus Diagnostics, Inc. has the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings, Inc (OTCQX: AMBS) is focused on developing treatments in the areas of Regenerative Medicine, and Orphan diseases. The Company acquired an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute (ESS) from Lonza. ESS is an autologous full thickness skin replacement product in development for the treatment of adult severe burns, currently preparing to enter Phase 2 clinical studies. The Company is currently evaluating human clinical data from previously conducted studies in pediatric severe burns and Congenital Giant Hairy Nevus to support clinical development expansion into those areas. ESS has achieved Orphan Drug Designation (ODD) in the area of severe burns, and is seeking ODD status for additional serious dermatologic indications. AMBS also has development rights to eltoprazine, a small molecule currently in clinical development for Parkinson's disease levodopa-induced dyskinesia, an orphan disorders with the potential to expand into adult ADHD and Alzheimer's aggression. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP) and retinal artery occlusion (RAO). AMBS also owns the technology platform that led to MANF's discovery (PhenoGuard™), and which can be used to identify novel neurotrophic factors.
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
Investor and Media Contact:
Ascendant Partners, LLC
SOURCE Amarantus BioScience Holdings, Inc.